Spectral AI Unveils Advanced AI-Powered Burn Measurement Technology

Spectral AI's Breakthrough in Burn Care Technology

Spectral AI, Inc. (NASDAQ:MDAI), a Dallas-based artificial intelligence company specializing in medical diagnostics, has announced the completion of a proof-of-concept for an advanced burn measurement module within its DeepView® System. This innovative technology aims to revolutionize burn care management by providing more accurate and standardized measurements of burn wounds 1

1

Advanced Measurement Capabilities

The new module addresses limitations in current wound measurement methods by offering:

1. Sub-millimetric accuracy in assessing burn wounds
2. Measurement of all three wound dimensions: distance, area, and volume
3. Rapid calculation of Total Body Surface Area (TBSA) affected by burns
4. No need for external markers or manual placement of stickers 2

   2

AI-Driven Healing Potential Assessment

The DeepView® System goes beyond measurement, offering:

• Immediate, objective, and binary assessment of a burn wound's healing trajectory
• Distinction between healing and non-healing tissue on the first day of assessment
• Support for clinical decision-making regarding treatment plans 1

  1

Potential Impact on Burn Care

Peter M. Carlson, CEO of Spectral AI, emphasized the technology's potential to:

1. Improve standardization and uniformity in burn care
2. Reduce human error in wound assessment
3. Provide crucial support to clinicians across various care settings 2

   2

Related Stories

Spectral AI Advances Burn Study with Expanded Clinical Trial Sites and Increased Patient Enrollment

Spectral AI Expands Clinical Trial Sites and Strengthens Patent Portfolio

Spectral AI Expands AI-Driven Burn Assessment Technology to Australia

Spectral AI Announces Q4 and Full Year 2024 Financial Results Conference Call

Company Developments and Financial Overview

Spectral AI has made significant strides in its operations:

• Completed patient enrollment for U.S. Burn Pivotal Study
• Secured over $850,000 from the Medical Technology Enterprise Consortium
• Projected 55% year-over-year increase in R&D revenue for 2024
• Expanded patent portfolio by 30%, now totaling 26 patents 1

  1

However, the company faces financial challenges:

• Market capitalization of $17.78 million
• Not currently profitable, with a negative P/E ratio
• Recent stock price decline of 30.82% over the past month 1

  1

Future Outlook and Regulatory Plans

Spectral AI aims to:

1. Submit a De Novo request to the FDA in Q2 2025 for classification of DeepView AI®-Burn as a Class II medical device
2. Continue development of the handheld predictive burn wound healing device, DeepView SnapShot M®
3. Expand clinical trial sites for the 2024 Burn Pivotal Study 1

   1

   2

   2

As Spectral AI advances its AI-driven diagnostic tools, the company positions itself at the forefront of medical technology innovation, potentially transforming burn care management and treatment decision-making processes.